Comparable long-term effectiveness to standard of care corticosteroids over 5 years Normal growth maintained, in contrast to growth suppression ...
The 54th International Symposium on High Performance Liquid Phase Separations and Related Techniques (HPLC 2025), was held from June 15–19, 2025, in Bruges, Belgium. This “Column Watch” installment ...
Objectives To describe the features and rates of emergency department (ED) presentations identified as related to violence against women (VAW) and of confirmed cases of family domestic violence (FDV) ...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that five posters will be presented in collaboration with independent investigators highlighting new data on LUPKYNIS ® (voclosporin) at the ...
SAN DIEGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that ...
RADNOR, Pa. and SOUTH SAN FRANCISCO, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Quanta Therapeutics, a privately-held clinical-stage biopharmaceutical company leading the development of innovative, ...
WATERTOWN, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the ...
Abstract: The fusion of hyperspectral images (HSIs) and multispectral images (MSI) aims to synthesize high-resolution hyperspectral image (HR-HSI) from observable low-resolution hyperspectral image ...
Pulse Biosciences Announces Presentation of Late-Breaking Data From the nPulse™ Cardiac Surgical System First-in-Human Feasibility Study at the 39th European Association for Cardio-Thoracic Surgery ...
Abstract: Signature estimation is critical for source evaluation and data processing. Far-field measurement is an accurate way to deterministically finalize the process and more importantly to clarify ...
Icotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event rates to placebo in Phase 3 ICONIC-ADVANCE studies Icotrokinra also showed ...
cDepartment of Maternal, Newborn, Child and Adolescent Health, and Ageing, Imperial College London, London, UK dDepartment of Epidemiology and Biostatistics, Imperial College London, London, UK ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results